SASLT guidelines: Update in treatment of Hepatitis C virus infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia.Saudi medical journal · 2021
   Guideline
2. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease.Journal of pharmacy & bioallied sciences · 2024
   Article
3. Beyond genotype-4: Direct-acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia.Health science reports · 2024
   Article
4. The Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Hepatitis C Virus in Saudi Arabia: A Nationwide Study Based on the Saudi Ministry of Health Surveillance Data From 2017 to 2021.Cureus · 2023
   Article
5. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital.Tropical medicine and infectious disease · 2023
   Article
6. A novel candidate hepatitis C virus genotype 4 subtype identified by next generation sequencing full-genome characterization in a patient from Saudi Arabia.Frontiers in microbiology · 2023
   Article
7. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
   Article
8. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia.Journal of epidemiology and global health · 2020
   Article
9. Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia.Journal of pharmacy & bioallied sciences
   Article
10. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Observational
11. Nonalcoholic fatty liver disease: One more reason to strengthen public health.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
12. Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
13. Hepatitis c eradication: It's now or never…let's get to work.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article

Corrections and comments

• Commented on by
  Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients.

Authors and funding

10 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as